LGM Pharma is a Reteplase CAS# 133652-38-7 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
Questions? Call our customer API support number 1-(800)-881-8210.
LGM Pharma offers this active ingredient but not the finished dosage forms.
CAS No: 133652-38-7
Synonyms: t- PA t-plasminogen activator Tissue-type plasminogen activator precursor tPA
ATC Code: B01AD07
Chemical Formula: C12H21N
Molecular Weight: 39589.6
Assay/Purity: Typically NLT 98%
DrugBank: DB00015 (BIOD00013, BTD00013)
For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction
Reteplase cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.
Mode of Action:
Reteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.
API’s From Quality Manufacturers:
Cost effective materials based on specific requirements
Small quantities for initial research and larger development quantities towards product commercialization
Technical packages, letters of access to filed DMFs